Skip to main content
SpringerLink
Log in

Gene Polymorphisms for PAI-1 Are Associated with the Angiographic Extent of Coronary Artery Disease

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Localized regulation of fibrinolytic protein gene expression is associated with the histologic extent of atherosclerosis. This regulation may be dependent on the presence of certain fibrinolytic protein gene polymorphisms. The relationship between the plasminogen activator inhibitor (PAI)-1 HindIII and the tissue plasminogen activator (t-PA) EcoR1 gene polymorphisms and the extent of coronary artery disease (CAD) were investigated in 49 Caucasian patients with symptomatic CAD. There was a strong association between PAI-1, but not t-PA, gene polymorphisms and the extent of CAD detected by coronary angiography. Patients homozygous for the presence or absence of the PAI-1 HindIII (1/1, 2/2 PAI-1) gene polymorphisms had a significantly greater extent of CAD (number of diseased vessels) than patients with the respective heterozygous forms (vs. 1/2 PAI-1, P = 0.05). Stepwise ordinal multiple regression analysis of classic CAD risk factors and fibrinolytic protein genotypes indicated that only the PAI-1 genotypes were predictive of the extent of angiographic CAD (P = 0.019). Analysis of variance between classic risk factors and fibrinolytic protein genotypes identified an association between t-PA genotypes and a history of prior infarction or stroke. Fibrinolytic gene polymorphisms for PAI-1 are associated with the extent of CAD in symptomatic patients and with certain risk factors for coronary atherosclerosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Hamsten A. Hemostatic function and coronary artery disease. N Engl J Med 1995;332:677–678.

    PubMed  Google Scholar 

  2. Aznar J, Estelles A, Tormo G, Sapena P, Tormo V, Blanch S, Espana F. Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. Br Heart J 1988;59:535–541.

    PubMed  Google Scholar 

  3. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller G. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993;342:1076–1079.

    PubMed  Google Scholar 

  4. Hamsten A, Walldius G, Szamosi A, et al. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987;3–9.

  5. Jansson JH, Nilsson TK, Olofsson BO. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J 1991;12:157–161.

    PubMed  Google Scholar 

  6. Munkvad S, Gram J, Jespersen J. A depression of active tissue plasminogen activator in plasma characterizes patients with unstable angina pectoris who develop myocardial infarction. Euro Soc Cardiol 1990;525–528.

  7. Ridker PM, Hennekens C, Stampfer MJ, Manson JE, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet 1994;343: 940–943.

    PubMed  Google Scholar 

  8. Eliasson B, Attvall S, Taskinen M, Smith U. The insulin resistance syndrome in smokers is related to smoking habits. Arterioscler Thromb 1994;14:1946–1950.

    PubMed  Google Scholar 

  9. Mehta J, Mehta P, Lawson D, Saldeen T. Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: Correlation with age and serum triglyceride concentrations. J Am Coll Cardiol 1987;9:263–268.

    PubMed  Google Scholar 

  10. Fontbonne A, Charles MA, Thibult N, et al. Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population: The Paris Prospective Study, 15-year follow-up. Diabetologia 1991;34:356–361.

    PubMed  Google Scholar 

  11. Auwerx JH, Bouillon R, Collen D, Geboers J. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 1988;8:68–72.

    PubMed  Google Scholar 

  12. Sawa H, Sobel BE, Fujii S. Potentiation by hypercholesterolemia of the induction of aortic intramural synthesis of plasminogen activator inhibitor type 1 by endothelial injury. Circ Res 1993;73:671–680.

    PubMed  Google Scholar 

  13. Genest J, Cohn JS. Clustering of cardiovascular risk factors: Targeting high-risk individuals [review]. Am J Cardiol 1995;76:8–20.

    Google Scholar 

  14. Vague P, Raccah D, Scelles V. Hypofibrinolysis and the insulin resistance syndrome [review]. Int J Obes Relat Metab Disord 1995;19:11–15.

    PubMed  Google Scholar 

  15. Andersen P. Hypercoagulability and reduced fibrinolysis in hyperlipidemia: Relationship to the metabolic cardiovascular syndrome [review]. J Cardiovasc Pharmacol 1992;20: 29–31.

    Google Scholar 

  16. Juhan-Vague I, Alessi MC. Plasminogen activator inhibitor 1 and atherothrombosis. Thromb Haemost 1993;70:138–143.

    PubMed  Google Scholar 

  17. ECAT Angina Pectoris Study Group. ECAT angina pectoris study: Baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 1993;14:8–17.

    Google Scholar 

  18. Paramo JA, Colucci M, Collen D. Plasminogen activator inhibitor in the blood of patients with coronary artery disease. Br Med J 1985;291:573–574.

    Google Scholar 

  19. Oloffon BO, Dahlen G, Nilsson TK. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically certified coronary artery disease. Eur Soc Cardiol 1989;77–82.

  20. Padro T, Emeis JJ, Steins M, Schmid KW, Kienast J. Quantification of plasminogen activators and their inhibitors in the aortic vessel wall in relation to the presence and severity of atherosclerotic disease. Arterioscler Thromb Vasc Biol 1995;15:893–902.

    PubMed  Google Scholar 

  21. Chomiki N, Henry M, Alessi MC, Anfosso F, Juhan-Vague I. Plasminogen activator inhibitor-1 expression in human liver and healthy o atherosclerotic vessel walls. Thromb Haemost 1994;72:44–53.

    PubMed  Google Scholar 

  22. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 1992;89: 6998–7002.

    PubMed  Google Scholar 

  23. Lupu F, Bergonzelli GE, Heim Da, Cousin E, Genton CY, Bachmann F, Kruithof EKO. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb 1993;13: 1090–1100.

    PubMed  Google Scholar 

  24. Kenagy RD, Clowes AW. Regulation of baboon arterial smooth muscle cell plasminogen activators by heparin and growth factors. Thromb Res 1995;77:55–61.

    PubMed  Google Scholar 

  25. Pepper MS, Vassalli JD, Wilks JW, Schweigerer L, Orci L, Montesano R. Modulation of bovine microvascular endothelial cell proteolytic properties by inhibitors of angiogenesis. J Cell Biochem 1994;55:419–434.

    PubMed  Google Scholar 

  26. Spencer-Green G. Retinoic acid effects on endothelial cell function: Interaction with interleukin 1. Clinl Immunol Imunopathol 1994;72:53–61.

    Google Scholar 

  27. Landin K, Tengborn L, Smith U. Effects of metformin and metoprolol CR on hormones and fibrinolytic variables during a hyperinsulinemic, euglycemic clamp in man. Thromb Haemost 1994;71:783–787.

    PubMed  Google Scholar 

  28. Seljeflot I, Eritsland J, Torjesen P, Arnesen H. Insulin and PAI-1 levels during oral glucose tolerance test in patients with coronary heart disease. Scand J Clin Lab Invest 1994; 54:241–246.

    PubMed  Google Scholar 

  29. Jespersen J, Munkvad S, Gram JB. The fibrinolysis and coagulation systems in ischaemic heart disease. Risk markers and their relation to metabolic dysfunction of the arterial intima. [review]. Dan Med Bull 1993;40:495–502.

    PubMed  Google Scholar 

  30. Mussoni L, Mannucci L, Sirtori M, Camera M, Maderna P, Sironi L, Tremoli E. Hypertriglyceridemia and regulation of fibrinolytic activity. Arterioscler Thromb 1992;12:19–27.

    PubMed  Google Scholar 

  31. Ye S, Green FR, Scarabin PY, et al. Cambien F. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM Study. Thromb Haemost 1995; 74:837–841.

    PubMed  Google Scholar 

  32. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993;268:10739–10745.

    PubMed  Google Scholar 

  33. Dawson SJ, Hamsten A, Wiman B, Henney A, Humphries S. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 1991; 11:183–190.

    PubMed  Google Scholar 

  34. Eriksson P, Kallin B, van 'T Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995; 92:1851–1855.

    PubMed  Google Scholar 

  35. Mansfield MW, Stickland MH, Grant PJ. Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes. Thromb Haemost 1995;74:1021–1034.

    Google Scholar 

  36. Degen SJF, Rajput B, Reich E. The human tissue plasminogen activator gene. J Biol Chem 1986;261:6972–6985.

    PubMed  Google Scholar 

  37. Klinger KW, Winqvist R, Riccio A, et al. Plasminogen activator inhibitor type 1 gene is located at region q21.3-q22 of chromosome 7 and genetically linked with cystic fibrosis. Proc Natl Acad Sci USA 1987;84:8548–8552.

    PubMed  Google Scholar 

  38. Maniatis T, Fritsch EF, Sambrook J. Synthetic oligonucleotide probes. In: Irwin N, Ford N, Nolan C, Ferguson M, Ockler M, eds. Molecular Cloning: A Laboratory Manual, 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1982:1–61.

    Google Scholar 

  39. Mussoni L, Madema P, Camera M, et al. Atherogenic lipoproteins and release of plasminogen activator inhibitor-1 (PAI-1) by endothelial cells. Fibrinolysis 1990;4:79–81.

    Google Scholar 

  40. Sundell IB, Nilsson TK, Hallmans G, Hellsten G, Dahlen GH. Interrelationships between plasma levels of plasminogen activator inhibitor, tissue plasminogen activator, lipoprotein (a), and established cardiovascular risk factors in a north Swedish population. Atherosclerosis 1989;80: 9–16.

    PubMed  Google Scholar 

  41. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993;341: 1165–1168.

    PubMed  Google Scholar 

  42. Reilly JM, Sicard GA, Lucore CL. Abnormal expression of plasminogen activators in aortic aneurysmal and occlusive disease. J Vasc Surg 1994;19:865–872.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama

    Raymond L. Benza, Hernan Grenett, Xin-Nong Li, Van C. Reeder, Steven L. Brown, Gilbert J. Perry & Francois M. Booyse

  2. Department of Epidemiology, University of Alabama at Birmingham, Birmingham, Alabama

    Rodney C.P. Go & Kathryn A. Hanson

  3. Department of Surgery, Division of Cardiothoracic Surgery, University of Alabama at Birmingham, Birmingham, Alabama

    William L. Holman & David C. McGiffin

  4. Department of Biostatistics, University of Alabama at Birmingham, Birmingham, Alabama

    Katherine A. Kirk

Authors
  1. Raymond L. Benza
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hernan Grenett
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xin-Nong Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Van C. Reeder
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Steven L. Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rodney C.P. Go
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kathryn A. Hanson
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Gilbert J. Perry
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. William L. Holman
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. David C. McGiffin
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Katherine A. Kirk
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Francois M. Booyse
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Benza, R.L., Grenett, H., Li, XN. et al. Gene Polymorphisms for PAI-1 Are Associated with the Angiographic Extent of Coronary Artery Disease. J Thromb Thrombolysis 5, 143–150 (1998). https://doi.org/10.1023/A:1008882113177

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1008882113177

Search

Navigation